USD10
SYRE Shares
About Spyre TherapeuticsSpyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
USD10
SYRE Shares
About Spyre TherapeuticsSpyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$8.7B
OPEN PRICE
$94.26
LOW (1Y)
$14.51
HIGH (1Y)
$105.09
LOW (24H)
$92.37
HIGH (24H)
$101.36
VOLUME (24H)
$1.09M
20.37%
Price history
Time | Price | Change |
|---|---|---|
Today | $94.26 | |
1 Day | $93.55 | |
1 Week | $95.72 | |
1 Month | $88.44 | |
1 Year | $16.35 |
Past performance is not a reliable indicator of future results.
Discover more
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.